Tosh is the first
St. Jude patient to reach this milestone and was recognized at institution’s 60th anniversary celebration
New collaboration with multiple organizations is part of national effort to provide equity in STEM education.
St. Jude immunologists identified proteins that help decide T cell fate and used the finding to improve CAR-T cell therapy in a solid tumor model.
St. Jude Children’s Research Hospital recognized among hospitals delivering exceptionally high-quality care
St. Jude scientists identified a genetic difference in childhood cancer survivors treated with chemotherapy that predisposes them to heart problems as adults.
St. Jude scientists are studying how the temperature at which protein structures are captured can create "artifacts," – errors that cause misleading results.
Learn best practices and hear insights from
St. Jude oncologists, psychologists and scientists at the annual gathering of clinical oncology experts.
St. Jude scientists uncovered how one type of T cell creates two genetically identical, but functionally different, daughter cells.
This the first time researchers have identified the mechanism for closed-state inactivation. These approaches could be applied to other ion channels.
St. Jude scientists identified ZBP1 as a key contributor to the inflammatory cell death that drives morbidity and mortality in COVID-19 patients.
St. Jude scientists will discuss research on cellular therapies for pediatric cancer and more at the annual meeting.
Big data can cause big problems in rare disease genetics research. Scientists at
St. Jude created a systematic solution to find the inherited genes contributing to rare disease.
St. Jude demonstrate the role of chromatin regulation in cancer’s resistance to EZH2 inhibitors and offer a way to make treatment more effective.
RMS is the most common soft tissue sarcoma in children. When it recurs after therapy, the survival rate is only 30%.
St. Jude scientists and their Columbia University collaborators reveal how GPCR signaling is regulated with implications for drug development.
St. Jude scientists have found the first known example of a promoter ‘donation’ event from a retrotransposon causing a highly malignant childhood brain cancer.
Dr. Taylor steps into the role during a pivotal time of growth for
St. Jude, as its scientific enterprise will significantly expand.
Dr. Amar Gajjar becomes the seventh
St. Jude Children’s Research Hospital investigator to receive the Pediatric Oncology Award
The AACR also honored the
St. Jude scientist for her contributions to advancing women in science.
St. Jude researchers are recognized by the American Society of Pediatric Hematology/Oncology for their expertise and career achievements
St. Jude scientists have studied how vaccination before and after primary infections affect the immune response.
St. Jude Children’s Research Hospital will participate in the annual gathering of a premier professional society for the cancer research community.
Four more Ukrainian children with cancer and their 11 family members arrived at
St. Jude Children’s Research Hospital in Memphis, Tennessee.
St. Jude continues to help move hundreds of Ukrainian children with cancer to safety so they can continue treatment.
Dr. Downing is honored for his outstanding contributions and innovations in cancer research.
St. Jude Children’s Research Hospital findings lay the groundwork for identifying pediatric cancer survivors at higher risk of accelerated aging and chronic diseases.
Private, comfortable space in newly designed airport concourse will be staffed by
St. Jude employees.
On Saturday, the Foundation’s building in Bocheniec, now officially named the Unicorn Marian Wilemski Clinic, welcomed the first group of Ukrainian children and their families. Read more about this ongoing effort.
Emphasizing the need for HPV vaccination, the campaign launches March 4, 2022, International HPV Awareness Day.
St. Jude scientists have found a previously overlooked mutation in a subtype of pediatric leukemia that has implications for identifying high-risk patients.
The hospital relocates 500 administrative employees to the temporary workspace during the construction phase of its six-year strategic plan.
St. Jude scientists blocked development of acute lymphoblastic leukemia in mice with a genetic mutation that increases the risk of childhood cancer.
Diamond jubilee events are planned nationwide for supporters to honor
St. Jude visionaries, recognize expanding global impact of scientific, medical achievements
St. Jude scientists have shown that the active immune system in young hosts may actually work against cancer immunotherapies by exhausting T cells.
St. Jude have revealed how an inherited genetic variant turns on an oncogene, increasing the risk of developing childhood leukemia. Published in Nature Genetics.
St. Jude scientists created an immunotherapeutic strategy for a type of pediatric leukemia using CAR T cells that target a tumor-specific antigen.
St. Jude scientists show that addressing racial disparities in acute lymphoblastic leukemia should include considering how genetic ancestry affects biology and prognosis.
St. Jude study also suggests that prior immunity to common cold coronaviruses does not protect against SARS-CoV-2 infection.
St. Jude identified distinct functions for regions of a super-enhancer that controls gene expression during retina formation, calling it a ‘modular’ super-enhancer.
St. Jude have captured the structure of autoactivated BAK, a key protein for triggering apoptosis in cancer cells.